Biomea Fusion presents icovamenib diabetes data at ADA 2026

Biomea Fusion has unveiled a package of clinical and translational data for icovamenib, its oral menin inhibitor, at the American Diabetes Association's 86th Scientific Sessions in New Orleans. The results, drawn from the Phase II COVALENT-111 and COVALENT-112 studies, indicate the candidate can improve endogenous insulin secretion across both major forms of diabetes while appearing well tolerated over a 52-week period.

The most striking headline figure comes from the T2D subgroup analysis. Among patients in COVALENT-111 who remained above glycaemic targets despite receiving a background GLP-1 receptor agonist, those treated with icovamenib achieved a mean HbA1c reduction of 1.2% at Week 52, compared with a mean increase of 0.6% in the placebo arm — a placebo-adjusted difference of 1.8 percentage points. Notably, that improvement was sustained 40 weeks after treatment was stopped, which the company attributes to restoration of beta cell function rather than a simple pharmacological effect.

Beta cell preservation in type 1 diabetes

In the COVALENT-112 study, icovamenib was evaluated in adults with T1D, a notoriously difficult target given the autoimmune aetiology of the disease. Among participants diagnosed within three years of enrolment and treated with the 200 mg daily dose, C-peptide area under the curve rose by approximately 52% at Week 12 versus baseline. By Week 52, the mean C-peptide AUC was about 7% below baseline — a markedly more favourable trajectory than the approximately 47% annual decline observed in historical placebo cohorts. Cytokine profiling found no evidence of systemic immune activation throughout, which Biomea's interim chief executive Mick Hitchcock described as "critical in ensuring lasting benefits for patients."

Translational data presented alongside the clinical readouts suggest icovamenib may activate pathways beyond glycaemic control, including GLP-1 receptor expression in human islets, pro-myogenic effects in skeletal muscle cells, and browning of adipocytes — observations that the company argues support investigation in obesity and as a complement to existing GLP-1 therapies. These findings are from cell models and should be interpreted accordingly; translating such signals into clinical benefit requires further in-vivo and clinical study.

BMF-650 expansion and the broader GLP-1 landscape

Separately, Biomea announced the addition of a new cohort to the Phase I GLP-131 study of BMF-650, its oral small-molecule GLP-1 receptor agonist. The new arm will test a rapid one-step up-titration — 200 mg once daily for one week, escalating to 400 mg once daily for three weeks — to explore whether a compressed dosing schedule can optimise weight reduction. Initial 28-day weight data from the study are expected in the third quarter of 2026.

The oral GLP-1 space is becoming crowded. Eli Lilly's orforglipron is in late-stage development, and Novo Nordisk has its own oral semaglutide already on the market. Biomea's disclosure that BMF-650 is "related to the broader orforglipron chemotype" positions it as a next-generation entrant hoping to differentiate on bioavailability and tolerability rather than mechanism. Whether a clinical-stage company with limited resources can carve out a durable position against well-capitalised incumbents remains the central commercial question.

For icovamenib, the menin inhibitor class has attracted attention in oncology — particularly in MLL-rearranged leukaemia — but Biomea is pursuing a distinct metabolic hypothesis. If the durability signal holds in larger trials, a short-course oral therapy that meaningfully preserves beta cell function would address a genuine unmet need; standard-of-care GLP-1 and SGLT2 therapies manage glucose but do not demonstrably restore the insulin-secreting capacity that declines progressively in both T1D and T2D. Biomea will need to advance into a Phase III programme to validate whether these Phase II signals are predictive of real-world benefit.